NCT05909644View on ClinicalTrials.gov

An Open-label DDI Study of Omaveloxolone in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions

Healthy Adult Subjects

Interventions

DRUG

Omaveloxolone

Omaveloxolone Capsules, 150 mg, administered orally

DRUG

Efavirenz

Efavirenz Tablet, 600 mg, administered orally once daily

Trial Locations (1)

85283

Celerion, Inc., Tempe

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors

collaborator

Celerion

INDUSTRY

collaborator

Q2 Solutions

INDUSTRY

collaborator

Altasciences Company Inc.

INDUSTRY

lead

Biogen

INDUSTRY